Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults…
20 analysts rate ASND Buy on consensus.
Consensus price target: $307.36 (+26.29% upside from $243.37)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Bodenhoff Mads SVP & PAO | Sep 8, 2026 | Sale | 3,000 | $810.57K |
| HOLTUG LARS director | Sep 2, 2026 | Sale | 236 | $62.33K |
| SMITH SCOTT THOMAS EVP & Chief Financial Officer | Jun 2, 2026 | Purchase | 100 | $21.9K |
| BIENAIME JEAN JACQUES director | May 26, 2026 | Purchase | 200 | $47.25K |
| BIENAIME JEAN JACQUES director | May 26, 2026 | Purchase | 200 | $47.87K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $775.05M | +90.22% | $-245.43M |
| 2024 | $407.46M | +36.34% | $-423.64M |
| 2023 | $298.85M | +421.2% | $-539.46M |
Stock data for ASND: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics